Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib Open-label Clinical Trial of Once Daily Oral Treatment of Afatinib Plus Weekly Intravenous Infusion of Xentuzumab (BI 836845) in Patients With EGFR Mutant Non-small Cell Lung Cancer With Progression Following Prior EGFR Tyrosine Kinase Inhibitor

Next Previous
Trial Profile

A Phase Ib Open-label Clinical Trial of Once Daily Oral Treatment of Afatinib Plus Weekly Intravenous Infusion of Xentuzumab (BI 836845) in Patients With EGFR Mutant Non-small Cell Lung Cancer With Progression Following Prior EGFR Tyrosine Kinase Inhibitor

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 30 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Xentuzumab (Primary) ; Afatinib
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Boehringer Ingelheim

Most Recent Events

  • 30 Apr 2018 Status changed from active, no longer recruiting to completed.
  • 29 Mar 2018 Planned End Date changed from 2 Mar 2018 to 26 Apr 2018.
  • 29 Mar 2018 Planned primary completion date changed from 2 Mar 2018 to 26 Apr 2018.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top